Melissa H. Boyd

Associate
Full contact info

Passions

Family

Traveling

Singing

Flamenco dance

Experience

Olive Hits $4 Billion Valuation With Latest Funding Round

July 9, 2021

Cooley advised digital health automation company Olive on its $400 million funding round, which brings its valuation to $4 billion. Lawyers Peter Werner and Melissa Boyd led the Cooley team advising Olive.

Read more

Related contacts

Peter H. Werner
Partner in Charge – San Francisco, San Francisco
Melissa H. Boyd
Associate, San Francisco
Jodie Bourdet
Partner, San Francisco
Eric M. Walder
Associate, San Francisco
Kim Merritt
Paralegal Specialist, San Francisco
Blake Martell
Partner, San Francisco

Related Practices & Industries

Nuvation Bio to Combine With Panacea, a Special Purpose Acquisition Company

February 17, 2021

Cooley advised oncology-focused biopharmaceutical company Nuvation Bio on its agreement to combine with Panacea, a special purpose acquisition company or SPAC, sponsored by EcoR1 Capital. Upon closing, which is expected in Q1 2021, Panacea will be renamed Nuvation Bio, and its common stock will be listed on the New York Stock Exchange under the new symbol “NUVB.” Cooley partners Kenneth Guernsey, Rama Padmanabhan and John McKenna led the team advising Nuvation on the agreement.

Read more

Related contacts

Kenneth Guernsey
Senior Counsel , San Francisco
Rama Padmanabhan
Partner, San Diego
John McKenna
Partner, Palo Alto
Melissa H. Boyd
Associate, San Francisco
Rajdeep Roger Bains
Associate, San Diego
Matthew D. Silverman
Special Counsel, San Diego
Ajay Athavale
Associate, San Francisco
Julia R. Brinton
Associate, Washington, DC
Eileen Marshall
Partner, Washington, DC

Related Practices & Industries

Olive Closes $225 Million Financing, Acquires Verata Health

December 23, 2020

Cooley advised healthcare software company Olive on its $225.5 million financing round led by Tiger Global, as well as its acquisition of Verata Health to accelerate artificial intelligence technology for healthcare providers and payers. Partner Peter Werner led the Cooley teams advising Olive on the transactions.

Read more

Related contacts

Peter H. Werner
Partner in Charge – San Francisco, San Francisco
Gaël Y. Hagan
Associate, Colorado
Melissa H. Boyd
Associate, San Francisco
Eric M. Walder
Associate, San Francisco
Blake Martell
Partner, San Francisco
Ajay Athavale
Associate, San Francisco
Jonathan Rivinus
Partner, Colorado
Rick Jantz
Associate, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Jennifer Shanley
Special Counsel, New York
Bryan Berman
Special Counsel, Colorado
Kristopher Kleiner
Special Counsel, Colorado
Ross Eberly
Partner, Los Angeles Santa Monica

Related Practices & Industries

Levi Strauss & Co. – $623 Million IPO

March 20, 2019

Cooley advised Levi Strauss on its $623 million initial public offering of 36,666,667 shares of common stock. Eric Jensen, Jodie Bourdet and Siana Lowrey led the Cooley team advising Levi Strauss.

Goldman Sachs and J.P. Morgan served as joint lead book-running managers for the offering. BofA Merrill Lynch, Morgan Stanley and Evercore Group served as book-running managers and BNP Paribas, Citigroup, Guggenheim Securities, HSBC, Drexel Hamilton, Telsey Advisory and The Williams Capital Group served as co-managers.

Levi Strauss is an iconic blue jeans and apparel company with products sold in more than 110 countries worldwide. The company’s shares now trade on the NYSE under the symbol “LEVI.”

Read more

Related contacts

Eric Jensen
Vice Chair, Palo Alto
Jodie Bourdet
Partner, San Francisco
Siana Lowrey
Partner, San Francisco
Melissa H. Boyd
Associate, San Francisco
Arielle H. Friehling
Associate, San Francisco
Kim Merritt
Paralegal Specialist, San Francisco
Barbara Mirza
Partner, Los Angeles Santa Monica
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Patrick Gibbs
Partner, Palo Alto
Jamie Leigh
Partner, San Francisco

Related Practices & Industries

Principia Biopharma – $122 Million IPO

October 3, 2018

Cooley advised Principia Biopharma on its $122.2 million initial public offering of 7,187,500 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares. Lawyers David Peinsipp, Drew Williamson, Barbara Kosacz and Amanda Busch led the Cooley team advising the company.

Bank of America Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as joint book-running managers for the offering. Robert W. Baird acted as lead manager.

Principia Biopharma, which now trades on the Nasdaq Global Select Market as “PRNB,” is a biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.

Related contacts

David Peinsipp
Partner, San Francisco
Drew Williamson
Partner, San Francisco
Barbara Kosacz
Senior Counsel, Palo Alto
Melissa H. Boyd
Associate, San Francisco
Anne Lieberman
Partner, Los Angeles Santa Monica

Related Practices & Industries